Creative Medical reports 93% response in Ultrasome pilot
- Creative Medical Technology Holdings reported a 93% study-defined response rate in its investigational Ultrasome knee osteoarthritis study, with 28 of 30 participants meeting response criteria.
- The group's average pain score declined approximately 65%, average WOMAC scores decreased 52%, and knee-related quality-of-life scores improved by approximately 35 points, with no serious adverse events reported.
- Creative Medical plans to submit detailed findings for peer-reviewed publication, but the open-label, single-arm study lacked a control group, limiting conclusions about treatment effectiveness.
Creative Medical Technology Holdings (NASDAQ:CELZ) reported that 28 of 30 patients, or 93%, met study-defined response criteria in its Ultrasome knee osteoarthritis pilot.
The six-month study showed a 65% reduction in the group's average pain score, although the absence of a control group limits interpretation of treatment effectiveness.
“With 93% of patients meeting study-defined response criteria and an approximately 65% reduction in the group's average pain score, we believe the results strengthen the rationale for further development,” said CEO Timothy Warbington.
Average WOMAC scores declined 52%, while knee-related quality-of-life scores improved approximately 35 points, with no serious adverse events reported during follow-up.
Creative Medical plans to submit its full scientific findings for peer-reviewed publication, while further controlled trials would be needed to establish clinical benefits.
The open-label study enrolled 30 adults with bilateral knee osteoarthritis and did not include randomized treatment assignment or a sham-controlled comparison group.
Ultrasome is an investigational cell-free regenerative medicine platform derived from the company's CELZ-201 technology, with laboratory findings indicating changes in markers associated with inflammation and cartilage degradation.
